1例ALK阳性肺腺癌患者使用克唑替尼导致严重肝损伤的病例分析  

A Case Study of a Patient with ALK-positive Lung Adenocarcinoma Using Crizotinib Leading to Severe Liver Injury

作　　者：杨凤霞 YANG Feng-xia(Chongqing Changshou District Traditional Chinese Medicine Hospital,Chongqing 401220,China)

机构地区：[1]重庆市长寿区中医院,重庆401220

出　　处：《海峡药学》2025年第2期93-95,共3页Strait Pharmaceutical Journal

摘　　要：目的 本文通过对1例ALK阳性肺腺癌患者使用克唑替尼出现严重肝损伤后,更换阿来替尼抗肿瘤治疗的病例进行分析,为临床实践提供经验教训。方法 通过监测患者转氨酶指标,观察患者肝损伤变化情况。结果 克唑替尼治疗导致严重肝损伤后,更换阿来替尼治疗期间患者转氨酶恢复并长期维持正常水平。结论 当克唑替尼导致严重肝损伤,且经减量使用后仍旧出现严重肝损伤时,阿来替尼可能是一种好的选择。OBJECTIVE This article analyzed a case of aletinib antitumor therapy in an ALK-positive lung adenocarcinoma patient who suffered severe liver injury after crizotinib,and provided lessons for clinical practice.METHODS To observe the changes of liver injury by monitoring the transaminase index of patients.RESULTS After severe liver injury caused by crizotinib treatment,aminotransferase recovered and maintained normal levels for a long time during aletinib replacement.CONCLUSION Aletinib may be a good choice when crizotinib causes severe liver injury and is still present after reduced dosage.

关 键 词：阿来替尼 病例报告 克唑替尼 肝毒性 非小细胞肺癌 

分 类 号：R969.4[医药卫生—药理学]